© 2022 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Sponsored in part by Daiichi Sankyo. Content independently developed by OncLive®
January 21st 2022
This article provides a summary of data on treatment approaches for HER2-positive breast cancer presented at conferences in 2021 and offers a review of how findings may affect clinical approaches to escalating or de-escalating therapy in patients with early-stage disease, optimally sequencing HER2-targeted therapy in patients with metastatic breast cancer, and selecting HER2-targeted agents based on the burden of CNS disease.